-
'1 Report prologue
-
Market Introduction
-
Definition 15
-
Scope of the Study
-
Assumptions
-
& Limitations 16
-
Assumptions 16
-
Limitations 16
-
Market Structure 17
-
Research Methodology
-
Research Process 19
-
Primary Research 20
-
Secondary Research 21
-
Market Size Estimation 22
-
Forecast Model 22
-
Market Dynamics
-
Introduction 24
-
Drivers 26
- Worldwide Rising Prevalence of Q fever Coupled
-
with Increasing Q Fever Hospitalization Rates 26
-
Rising Worldwide Cattle, Sheep, and Goat Population
- Growth
-
in the Risk Factors of Q Fever 26
-
Globally Growing Geriatric Population 26
-
Restraints 27
- High Cost of Diagnostic Tests 27
- Lack of Awareness
-
About Q Fever 27
-
Opportunity 27
-
Presence of Untapped Opportunities in the Asia-Pacific and African Regions 27
-
Market Trends 27
-
Macroeconomic Indicators
-
Market Factor Analysis
-
Porter’s Five Forces Model 30
-
Bargaining Power of Suppliers 30
- Bargaining Power of Buyers
- Threat
-
of New Entrants 31
-
Threat of Substitutes 31
-
Rivalry 31
-
Supply Chain Analysis 32
- R&D and Development 32
- Manufacturing 32
- Distribution &
-
Sales 32
-
Post-Sales Monitoring 33
-
Investment Feasibility Analysis 33
-
Pricing Analysis 34
-
Global Q Fever Market, By Type
-
Overview 36
-
Acute 37
-
Chronic 37
-
Global Q Fever Market, By Diagnosis
-
Overview 39
-
Serology Tests 40
-
Others 40
-
Global Q Fever Market,
-
By Treatment
-
Overview 42
-
Antibiotics 43
-
Surgery 43
-
Global Q Fever Market, By End-User
-
Overview 45
-
Patients 46
-
Hospitals 46
-
Others 47
-
Global Q Fever Market, By Region
-
Overview 49
-
Americas 51
- North America 52
- Latin America 56
-
Europe 57
- Germany 59
- France 60
- UK 61
- Italy 62
- Spain 63
- Rest of Europe 64
-
Asia-Pacific 65
- Japan 67
- China 68
- India 69
- Australia 70
- South Korea 71
- Rest of Asia-Pacific 72
-
Middle East & Africa
- UAE
- Saudi
-
Arabia 76
-
Oman 77
-
Kuwait 78
-
Qatar 79
-
Africa 80
-
Rest of Middle East & Africa 81
-
Company Profile
-
Merck KGaA 83
- Company Overview 83
- Financial Overview 83
- Products/Services Offered 83
- SWOT Analysis 84
- Key Developments
- Key
-
Strategies 84
-
Teva Pharmaceutical Industries Ltd 85
-
Company Overview 85
- Financial Overview 85
- Products/Services Offered 86
- Key Developments 86
- SWOT Analysis
- Key
-
Strategies 86
-
Pfizer Inc. 87
-
Company Overview 87
-
Financial Overview 87
-
Products/Services Offered 87
-
SWOT Analysis 88
- Key Developments 88
- Key Strategies 88
-
Basilea Pharmaceutica Ltd 89
- Company Overview 89
- Financial Overview
- Products/Services
-
Offered 90
-
Key Developments 90
-
SWOT Analysis 90
-
Key Strategies 90
-
Sanofi S. A. 91
-
Company Overview 91
-
Financial Overview 91
-
Products/Services Offered 91
-
SWOT Analysis 92
- Key Developments 92
- Key strategies 92
-
Melinta Therapeutics, Inc. 93
- Company Overview 93
- Financial Overview
- Products/Services
-
Offered 93
-
Key Developments 94
-
SWOT Analysis 94
-
Key Strategies 94
-
Bayer AG 95
-
Company Overview 95
-
Financial Overview 95
-
Products/Services Offered 95
-
SWOT Analysis 96
- Key Developments 96
- Key Strategies 96
-
Johnson & Johnson Services, Inc. 97
- Company Overview
- Financial
-
Overview 97
-
Products/Services Offered 97
-
SWOT Analysis 98
- Key Developments 98
- Key Strategies 98
-
Yashica Pharmaceuticals 99
- Company Overview 99
- Financial Overview
- Products/Services
-
Offered 99
-
Key Developments 99
-
SWOT Analysis 100
-
Key Strategies 100
-
AtoxBio 101
-
Company Overview 101
-
Financial Overview 101
-
Products/Services Offered 101
-
Key Developments 101
- SWOT Analysis 101
- Key Strategies 101
-
Appendix
-
Discussion Blue Print 103
-
List of Tables
-
MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 36
-
–2027 (USD THOUSAND) 37
-
(USD THOUSAND) 37
-
GLOBAL Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 39
-
MARKET, FOR SEROLOGY TESTS BY REGION, 2020–2027 (USD THOUSAND) 40
-
MARKET, FOR OTHERS BY REGION, 2020–2027 (USD THOUSAND) 40
-
FOR ANTIBIOTICS BY REGION, 2020–2027 (USD THOUSAND) 43
-
–2027 (USD THOUSAND) 43
-
GLOBAL Q FEVER MARKET, FOR PATIENTS BY REGION, 2020–2027 (USD THOUSAND) 46
-
MARKET, FOR HOSPITALS BY REGION, 2020–2027 (USD THOUSAND) 46
-
FOR OTHERS BY REGION, 2020–2027 (USD THOUSAND) 47
-
(USD THOUSAND) 50
-
AMERICAS: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 51
-
FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 51
-
BY TREATMENT, 2020–2027 (USD THOUSAND) 52
-
(USD THOUSAND) 52
-
NORTH AMERICA: Q FEVER MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND) 52
-
Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 53
-
–2027 (USD THOUSAND) 53
-
(USD THOUSAND) 53
-
NORTH AMERICAS: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 54
-
MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 54
-
(USD THOUSAND) 54
-
US: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 54
-
MARKET, BY END USER, 2020–2027 (USD THOUSAND) 55
-
(USD THOUSAND) 55
-
CANADA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 55
-
MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 55
-
(USD THOUSAND) 56
-
LATIN AMERICA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 56
-
Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 56
-
MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 56
-
–2027 (USD THOUSAND) 57
-
EUROPE: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 58
-
BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 58
-
(USD THOUSAND) 58
-
EUROPE: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 58
-
MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 59
-
(USD THOUSAND) 59
-
GERMANY: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 59
-
MARKET, BY END USER, 2020–2027 (USD THOUSAND) 59
-
(USD THOUSAND) 60
-
FRANCE: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 60
-
MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 60
-
(USD THOUSAND) 60
-
UK: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 61
-
BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 61
-
(USD THOUSAND) 61
-
UK: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 61
-
MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 62
-
(USD THOUSAND) 62
-
ITALY: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 62
-
MARKET, BY END USER, 2020–2027 (USD THOUSAND) 62
-
(USD THOUSAND) 63
-
SPAIN: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 63
-
MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 63
-
(USD THOUSAND) 63
-
REST OF EUROPE: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 64
-
Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 64
-
MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 64
-
–2027 (USD THOUSAND) 64
-
(USD THOUSAND) 65
-
ASIA-PACIFIC: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 65
-
Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 66
-
MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 66
-
–2027 (USD THOUSAND) 66
-
JAPAN: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 67
-
MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 67
-
(USD THOUSAND) 67
-
CHINA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 68
-
BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 68
-
(USD THOUSAND) 68
-
CHINA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 68
-
MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 69
-
(USD THOUSAND) 69
-
INDIA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 69
-
MARKET, BY END USER, 2020–2027 (USD THOUSAND) 69
-
(USD THOUSAND) 70
-
AUSTRALIA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 70
-
FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 70
-
BY END USER, 2020–2027 (USD THOUSAND) 70
-
(USD THOUSAND) 71
-
SOUTH KOREA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 71
-
Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 71
-
MARKET, BY END USER, 2020–2027 (USD THOUSAND) 71
-
TYPE, 2020–2027 (USD THOUSAND) 72
-
–2027 (USD THOUSAND) 72
-
(USD THOUSAND) 72
-
REST OF ASIA-PACIFIC: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND)
-
MIDDLE EAST & AFRICA: Q FEVER MARKET, BY COUNTRY, 2020–2027 (USD THOUSAND)
-
MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND)
-
MIDDLE EAST & AFRICA: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND)
-
MIDDLE EAST & AFRICA: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND)
-
MIDDLE EAST & AFRICA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND)
-
UAE: Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 75
-
BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 75
-
(USD THOUSAND) 75
-
UAE: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 75
-
Q FEVER MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 76
-
–2027 (USD THOUSAND) 76
-
(USD THOUSAND) 76
-
SAUDI ARABIA: Q FEVER MARKET, BY END USER, 2020–2027 (USD THOUSAND) 76
-
MARKET, BY TYPE, 2020–2027 (USD THOUSAND) 77
-
(USD THOUSAND) 77
-
OMAN: Q FEVER MARKET, BY TREATMENT, 2020–2027 (USD THOUSAND) 77
-
MARKET, BY END USER, 2020–2027 (USD THOUSAND) 77
-
(USD THOUSAND) 78
-
KUWAIT: Q FEVER MARKET, BY DIAGNOSIS, 2020–2027 (USD THOUSAND) 78
-
MARKET, BY TREATMENT, 2020&nda'